RT Journal Article
SR Electronic
T1 Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.02.21258076
DO 10.1101/2021.06.02.21258076
A1 Mahesh S Dhar
A1 Robin Marwal
A1 VS Radhakrishnan
A1 Kalaiarasan Ponnusamy
A1 Bani Jolly
A1 Rahul C. Bhoyar
A1 Viren Sardana
A1 Salwa Naushin
A1 Mercy Rophina
A1 Thomas A Mellan
A1 Swapnil Mishra
A1 Charles Whittaker
A1 Saman Fatihi
A1 Meena Datta
A1 Priyanka Singh
A1 Uma Sharma
A1 Rajat Ujjainiya
A1 Nitin Batheja
A1 Mohit Kumar Divakar
A1 Manoj K Singh
A1 Mohamed Imran
A1 Vigneshwar Senthivel
A1 Ranjeet Maurya
A1 Neha Jha
A1 Priyanka Mehta
A1 A Vivekanand
A1 Pooja Sharma
A1 VR Arvinden
A1 Urmila Chaudhary
A1 Namita Soni
A1 Lipi Thukral
A1 Seth Flaxman
A1 Samir Bhatt
A1 Rajesh Pandey
A1 Debasis Dash
A1 Mohammed Faruq
A1 Hemlata Lall
A1 Hema Gogia
A1 Preeti Madan
A1 Sanket Kulkarni
A1 Himanshu Chauhan
A1 Shantanu Sengupta
A1 Sandhya Kabra
A1 The Indian SARS-CoV-2 Genomics Consortium (INSACOG)
A1 Ravindra K. Gupta
A1 Sujeet K Singh
A1 Anurag Agrawal
A1 Partha Rakshit
YR 2021
UL http://medrxiv.org/content/early/2021/08/20/2021.06.02.21258076.abstract
AB Delhi, the national capital of India, has experienced multiple SARS-CoV-2 outbreaks in 2020 and reached a population seropositivity of over 50% by 2021. During April 2021, the city became overwhelmed by COVID-19 cases and fatalities, as a new variant B.1.617.2 (Delta) replaced B.1.1.7 (Alpha). A Bayesian model explains the growth advantage of Delta through a combination of increased transmissibility and partial reduction of immunity elicited by prior infection (median estimates; ×1.5-fold, 20% reduction). Seropositivity of an employee and family cohort increased from 42% to 86% between March and July 2021, with 27% reinfections, as judged by increased antibody concentration after previous decline. The likely high transmissibility and partial evasion of immunity by the Delta variant contributed to an overwhelming surge in Delhi.One-Sentence Summary Delhi experienced an overwhelming surge of COVID-19 cases and fatalities peaking in May 2021 as the highly transmissible and immune evasive Delta variant replaced the Alpha variant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupport from Ministry of Health and Family Welfare, Council of Scientific and Industrial Research, and Department of Biotechnology, India, is acknowledged.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SARSCoV2 genomic study was approved by the NCDC Ethics Review Committee vide approval 2020/NERC/14. The serology study was approved by the Institutional Human Ethics Committee of CSIRIGIB vide approval CSIR IGIB/IHEC/2019_20All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data is being continuously uploaded on the GISAID. https://www.gisaid.org/